DMAC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
DiaMedica Therapeutics Inc (DMAC) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has potential catalysts in the next 12-18 months as per analysts, the current technical indicators and financial performance do not provide compelling reasons to invest immediately. The lack of recent positive news, poor financial performance, and absence of significant trading signals suggest waiting for more clarity or a better entry point.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 39.593, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 8.137, and resistance is at 8.909. Overall, the technical indicators are mixed, with no strong buy signal.
Analysts have identified DiaMedica as a top idea for 2026, citing multiple meaningful catalysts over the next 12-18 months. The stock has a $14 price target, representing significant upside potential.
There is no recent news or significant trading activity from insiders, hedge funds, or Congress. Technical indicators are mixed, and there is no immediate signal from Intellectia Proprietary Trading Signals.
In Q3 2025, the company reported no revenue growth (0% YoY) and a 100% decline in net income and EPS. Gross margin remained at 0%. Overall, the financial performance is weak.
Lake Street maintains a Buy rating with a $14 price target, citing meaningful catalysts over the next 12-18 months. This represents a positive long-term outlook but does not provide immediate reasons to buy.
